Canasa

Mesalamine USP

Composition : Mesalamine USP 400mg Enteric Coated Delayed Release Tablet.

Indication : Mesalamine delayed release tablet is indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis.

Dosage and administration : For the treatment of mildly to moderately active ulcerative colitis: For Adults : The usual dosage in adults is two 400- mg tablets to be taken three times daily with or without food (for a total daily dose of 2.4 grams), for a duration of 6 weeks. For the maintenance of remission of ulcerative colitis: The recommended dosage in adults is 1.6 grams daily, in divided doses. Or, as directed by the registered physician

Use in pregnancy and lactation : Pregnancy category "C". There are no adequate & well controlled studies in pregnant women. Mesalamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Mesalamine & its N-acetyl metabolite are excreted into human milk. Caution should be exercised when Mesalamine is administered to nursing women.

Packing : Each box contains 3 x 10's tablets in blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.